

## 2<sup>nd</sup> Long-acting Treatment and Prevention Conference

Future of antiretrovirals in Africa: Long-acting agents and beyond

29 October 2024 | Johannesburg

# PROGRAMME

Start time	Topic	Speaker
<b>7:30</b>	<b>Arrival, registration and refreshments</b>	
8:30	Welcome and introduction by the Conference Chairpersons	Catherine Orrell and Nosisa Sipambo
8:35	Long-acting agents - where do these products fit in the African context?	Catherine Orrell
<b>New kids on the block: Industry Update</b>		
8:55	Long-acting injectable cabotegravir	Sibongile Kubheka
9:10	MK-8527 (and ISL) trials	TBA
9:25	Lenacapavir, a novel capsid inhibitor for HIV treatment and prevention	TBA
9:40	Q &A	All
<b>The Future of Long acting ARVs (Treatment)</b>		
9:50	Is injectable treatment as effective in maintaining viral suppression as standard oral ART?	Simiso Sokhela
10:10	From trial to implementation – can IMPALA help us jump across the gap?	Nigel Garrett
<b>10:30</b>	<b>Tea break</b>	
<b>The Future of Long acting ARVs (Treatment)</b>		
11:00	What are the treatment options for patients with multidrug-resistant HIV-1 infection?	Mohammed Rassool
11:20	What is the role of lenacapavir in future first-line HIV treatment?	Francois Venter
11:40	How long-acting injectable ART could help adolescent and young adults	Lauren Jennings
12:00	Q & A	All
<b>The Future of Long acting ARVs (Prevention)</b>		
12:10	Pre-exposure prophylaxis in adolescent girls and young women at risk of HIV infection	Nkosiphile Ndlovu
12:30	Uptake and retention of adolescents and young adults in differentiated HIV prevention	Maryam Shahmanesh
12:50	Panel discussion	
<b>13:00</b>	<b>Lunch break</b>	
<b>Special populations:</b>		
14:00	LA medications: Where do they fit in for niche populations in an African context?	Lee Fairlie
14:30	Long-acting PrEP in Pregnancy and Breastfeeding	Dvora Joseph Davey
15:00	Advancements in Neonatal HIV Therapy	Adrie Bekker
15:20	Progress towards bringing Long-acting ART to children and adolescents	Mo Archary
15:40	Q & A	All
<b>15:50</b>	<b>Tea break</b>	
<b>Implementation: TIME FOR ACTION</b>		
16:20	Assessing the demographic, risk profile, and clinical characteristics of early PrEP adopters	Pippa Macdonald
16:40	PrEP LA implementation in Botswana	Ava Avalos
17:00	LA implementation in Zambia	Lloyd Mulenga
17:20	South African perspective - where are with implementation, and what is the plan?	Hasina Subedar
17:40	Discussion & Closing	Catherine Orrell and Nosisa Sipambo
18:00	End	